Intraperitoneal cisplatin and carboplatin in the management of ovarian cancer.
The intraperitoneal delivery of cisplatin or carboplatin in the management of ovarian cancer is based on a sound pharmacokinetic rationale. Objective responses, including surgically documented complete responses, have been observed in patients with ovarian cancer who have previously responded to systemic platinum-based therapy. A precise role for intraperitoneal cisplatin or carboplatin in the management of ovarian cancer remains to be defined.
Markman
M
M
Cleveland Clinic Cancer Center, OH.
D016190:Carboplatin / Q000008:administration & dosage* / Q000627:therapeutic use; D002945:Cisplatin / Q000008:administration & dosage* / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D007263:Infusions, Parenteral; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D016879:Salvage Therapy
D016190:Carboplatin; D002945:Cisplatin